News & Events
Anima Biotech Lighting The Way In Protein Translation
When: Aug. 1st, 2018
"With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light."
Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets
When: Jul. 23rd, 2018
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.
Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
“We are excited to collaborate with Lilly in the discovery of new drugs for some of the world’s most challenging diseases. Small molecule drugs work by binding to disease-causing proteins to modify their chemical activity but most proteins lack accessible binding sites and as result, many diseases remain without effective treatments. Anima’s Translation Control Therapeutics platform is a new strategy against these undruggable target proteins. Rather than attempt to drug them after they are already made, we discover drugs that work one step before, by inhibiting (decreasing) or increasing the actual production by ribosomes of those proteins. This different approach is based on our novel science and patented technology and we believe it can lead to many new drugs” said Yochi Slonim, Anima Biotech’s co-founder and CEO.
About Anima Biotech:
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable
targets. Strategically structured for collaborations with multiple pharma partners, Anima's cloud based platform combines new biology with proprietary image analysis and high performance big data software. Its underlying technology is protected by 5 granted patents and its science is backed by 14 peer-reviewed publications that resulted from a network of 17 academic collaborations. The platform was validated by Anima's fast growing pipeline programs in multiple therapeutic areas including Fibrosis, Viral infections, Oncology and Neuroscience.
International tRNA Conference 2018
When: Sep. 23rd, 2018 to Sep. 27th, 2018
Where: Strasbourg, France
Anima Biotech has participated and presented at the 27th International tRNA Conference “tRNA at the crossroad”.
This event brings together researchers from around the world studying the many aspects of tRNA biology.
Translational Control 2018
When: Sep. 4th, 2018 to Sep. 8th, 2018
Where: Cold Spring Harbor, USA
Anima Biotech has participated and presented at the sixteenth conference on Translational Control to be held at Cold Spring Harbor Laboratory.
2018 BIO International Convention
When: Jun. 4th, 2018 to Jun. 7th, 2018
Where: Boston, USA
Anima Biotech has participated and presented at the 2018 BIO International Convention.
The conference is hosted by the Biotechnology Innovation Organization who represents over 1,100 biotech companies, academic institutions, state biotech centers and related organizations across the US and over 30 other nations.
2018 Biotech Investment Showcase
When: May. 22nd, 2018 to May. 23rd, 2018
Where: London, United Kingdom
Anima Biotech has participated and presented at the BIOTECH INVESTMENT SHOWCASE organized by the Oxford Global Conferences Ltd.
The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees.
When: May. 15th, 2018 to May. 17th, 2018
Where: Tel-Aviv, Israel
Anima Biotech has participated at the 17th MIXiii-BIOMED 2018 Conference and Exhibition.
As the leading event of Israel’s life sciences industry, MIXiii-BIOMED has positioned itself throughout the years as the main annual meeting place for players of Israel’s healthcare industry with their colleagues from around the globe.
Genesis Drug Discovery 2018
When: May. 10th, 2018 to May. 11th, 2018
Where: Barcelona, Spain
Anima Biotech has participated and presented at the 2nd annual Genesis Drug Discovery
Genesis Drug Discovery (GDD) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.
Labiotech: "Anima Biotech Targets Protein Translation to Fight Diseases"
When: Apr. 13th, 2018
Anima Biotech was selected as the Biotech of the week by Labiotech, Europe’s Leading Biotech News Website.
BIO-Europe Spring 2018
When: Mar. 12th, 2018 to Mar. 14th, 2018
Where: Amsterdam, The Netherlands
Anima Biotech has participated and presented at BIO-Europe Spring 2018.
With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.